DISC MEDICINE INC

Disc Medicine (IRON) fell 4.38 % on Oct 23, 2026, trading at $75.03 with a $2.9 B market cap. The clinical‑stage biopharma focuses on red‑cell biology for serious hematologic disorders.

Disc Medicine (IRON) just raised $450M and sits near a $80 price level—ready to push its hematologic pipeline but facing volatility and dilution risks.

Disc Medicine (IRON) surged 38.86% in 24 hours, trading at $79.48 with a $3B cap – a striking rise amid solid biotech momentum. Explore the latest price, volume, and analyst outlook for this promising hematology player.

Disc Medicine’s Phase 3 APOLLO success and $350 M capital raise propel its bitopertin EPP therapy toward FDA approval, boosting stock and investor confidence.